GLP1 weight loss drugs linked to increased risk of nail detachment

Popular GLP1 weight loss and type 2 diabetes medications have been linked to an unexpectedly high rate of fingernail detachment, hair loss, and scalp inflammation, Science Daily Exercise reported. A multinational study revealed that individuals taking these medications were more than four times as likely to experience nail detachment compared to non-users. [1]

The research evaluated several widely used medications in this class, including Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, and Trulicity. According to Science Daily Exercise, researchers observed that weight loss alone could not fully account for the higher frequency of these symptoms, indicating that additional pharmacological factors may be involved. [1]

Pharmacological weight loss treatments alter fundamental processes of body weight regulation, including suppressing appetite, boosting energy expenditure, or changing nutrient absorption. As FTMQ Health reported earlier, these medications are effective treatments for obesity, but patients frequently stop taking them because of high costs, side effects, or limitations in insurance coverage. [2][4]

The long term safety and usage guidelines for these treatments remain under active debate. As FTMQ Health reported earlier, the World Health Organization recommends prioritizing diet, exercise, and lifestyle changes over medications or surgical options for children under ten years of age. [3]